CStone Pharmaceuticals (HKG:2616) began nationwide commercial supply of locally manufactured pralsetinib capsules in China, according to a Monday filing with the Hong Kong bourse.
The oncology drugmaker said the first batch shipment marks the establishment of a localized supply chain for the therapy.
CStone expects full-year 2026 sales revenue for pralsetinib capsules to exceed 300 million yuan, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.